No Picture
Trading Ideas

3 Under-The-Radar Dividend Stocks with over 9% Dividend Yield

Reading the news about the stock markets, it pays to remember that the giant corporations – the Apples and the Microsofts, the Walmarts and the Home Depots – have a habit of taking up all the available oxygen in the room. That is, they hog the headlines, and can obscure a view of the larger picture.That larger picture, examined with an eye for the unusual, can reveal some excellent stock deals. There are plenty of bargain deals in the equity markets, and they offer plenty of reasons for investors to look twice. We’ve used the TipRanks Stock Screener tool to …read more […]

No Picture
Trading Ideas

BREAKING: United Promotes Scott Kirby to CEO, Munoz Becomes Executive Chairman

United Airlines is reshuffling its executive team with Scott Kirby being promoted to CEO in a long-expected move, and Oscar Munoz shifting to executive chairman of the airline group’s board. The change will take place in May 2020 when United’s current chairman, Jane Garvey, will retire from the board. Munoz will serve as executive chairman […] …read more […]

No Picture
Trading Ideas

UPDATE 1-Kinder Morgan expects earnings to decline in 2020

Pipeline operator Kinder Morgan Inc on Thursday forecast a drop in core earnings next year, as growth from expansion projects would likely be offset by higher spending and lower contract rates on some of its gas and oil pipelines. Kinder Morgan would generate $5.1 billion of distributable cash flow in 2020, which is nearly 3% higher than the current forecast for 2019. It also said it would increase its dividend per common share in 2020 to $1.25 per share, while spending $2.4 billion on expansion projects and joint ventures next year. …read more […]

No Picture
Trading Ideas

UPDATE 1-Sage's oral depression therapy fails in late-stage trial; shares plunge

Sage Therapeutics Inc said on Thursday its experimental drug failed to improve condition of patients with severe depression in a late-stage study, setting up the drugmaker to lose about $4 billion in valuation when the market opens. The hotly anticipated data was expected to allow the company to widen its reach in the multi-billion dollar depression market it entered with its first-approved drug, Zulresso, for postpartum depression. SVB Leerink analyst Marc Goodman had said in a note ahead of the trial results that a late-stage trial failure would be a major disappointment to investors and a setback for …read more […]